Atrial Fibrillation (AF)COMBINE-AFNCT07633509
The COMBINE-AF Trial
A study testing Linear ablation of mitral isthmus and tricuspid isthmus, Ethanol and Radiofrequency Ablation Catheter in people with Atrial Fibrillation (AF) and Atrial Fibrillation Catheter Ablation, run by Yunlong Wang at 3 sites in China.
Trial summary
The goal of this clinical trial is to test if a more complete ablation procedure works better than the standard procedure for people with long-lasting persistent atrial fibrillation (AF). AF is a heart rhythm problem that can cause a fast or uneven heartbeat. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Atrial Fibrillation (AF), Atrial Fibrillation Catheter Ablation
- What is being tested?
- Linear ablation of mitral isthmus and tricuspid isthmus, Ethanol and Radiofrequency Ablation Catheter
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 430 participants
- Where
- 3 sitesChina
- Study dates
- 27 Jul 2026to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Symptomatic patients with long-standing persistent atrial fibrillation.
- Duration of atrial fibrillation between 1 and 3 years.
- Age 18 to 75 years.
- Documentation of atrial fibrillation within 3 years prior to enrollment.
- Willing and able to comply with the study protocol and provide written informed consent.
Who cannot join
- Paroxysmal atrial fibrillation, or evidence of sinus rhythm on electrocardiogram within the past year.
- Persistent atrial fibrillation lasting less than 1 year or more than 3 years.
- Left atrial thrombus.
- Prior catheter ablation for atrial fibrillation.
- Coexisting severe organic heart disease (e.g., severe valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.).
- Left atrial diameter (LAD) >55 mm.
Show all 30Show fewer
- Left ventricular ejection fraction (LVEF) <40%.
- Known allergy or contraindication to low-molecular-weight heparin, warfarin, or direct oral anticoagulants.
- Undergoing a "one-stop" procedure combining atrial fibrillation ablation with left atrial appendage closure.
- Allergy to alcohol or contrast media.
- Pulmonary artery systolic pressure >50 mmHg.
- Unstable angina pectoris.
- Percutaneous coronary intervention (PCI) within the past 3 months.
- Cardiac surgery within the past 6 months.
- Planned heart transplantation.
- History of thromboembolic disease within the past 6 months (including venous thromboembolism: pulmonary embolism, deep vein thrombosis; or arterial thromboembolic disease: acute coronary syndrome, lower extremity arterial embolism, stroke).
- Left atrial myxoma.
- Severe respiratory disease.
- Active infectious disease.
- Poorly controlled or active systemic immune disease (equivalent to glucocorticoid use >2 tablets/day).
- Unresolved malignant hematologic disease, or currently receiving chemotherapy, radiotherapy, or immunotherapy.
- Unresolved malignant solid tumor, or currently receiving chemotherapy, radiotherapy, or immunotherapy.
- Untreated hypothyroidism or hyperthyroidism.
- Severe hepatic insufficiency (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3 times the upper limit of normal).
- End-stage renal failure requiring dialysis.
- Other serious arrhythmias, such as hemodynamically unstable ventricular tachycardia.
- Pregnancy or breast-feeding.
- Psychiatric disorder.
- Body mass index (BMI) <18.5 or >35.0 kg/m².
- Life expectancy <2 years.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Yijie Liu, PhD contact
China3 sites
Fuwai Hospital
Beijing, Beijing Municipality, 100039
Min Tang, PhD, +86 10 68314466, doctortangmin@yeah.net
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 101118
Yunlong Wang, PhD, +86 10 81992202, yunlong76818@126.com
Yijie Liu, PhD, yj-sage@qq.com
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University , Jiangsu Women and Children Health Hospital）
Nanjing, Jiangsu, 210029
Fengxiang Zhang, PhD, +86-25-83714511, njzfx6@njmu.edu.cn
About this study
Official title: A Multicenter, Prospective, Randomized Controlled Trial of Combined Pulsed-Field and Radiofrequency-Modified Linear Ablation Versus Pulsed-Field Ablation Alone for Long-Standing Persistent Atrial Fibrillation
The goal of this clinical trial is to test if a more complete ablation procedure works better than the standard procedure for people with long-lasting persistent atrial fibrillation (AF). AF is a heart rhythm problem that can cause a fast or uneven heartbeat.
This study will include 430 people with long-lasting AF that has lasted 1 to 3 years. Participants will be put into one of two groups by chance:
Read more
First group (control): They will receive pulsed-field ablation (PFA), a type of energy that can stop the faulty heart signals. They will have isolation of the pulmonary veins and the posterior wall of the left atrium.
Second group (study): They will receive the same PFA procedure plus extra ablation lines (modified linear ablation) using radiofrequency energy. This includes ablation of the mitral isthmus (with ethanol infusion into a small vein called the vein of Marshall) and the cavotricuspid isthmus.
Participants will be followed for 12 months after the procedure with clinic visits, electrocardiograms (ECGs), and heart rhythm monitors. The main outcome is whether participants stay in normal heart rhythm (sinus rhythm) without any AF episodes lasting more than 30 seconds at 12 months. Researchers will also look at procedure time, complication rates, quality of life, and other rhythm outcomes.
This study will help show if the more complete ablation procedure leads to better long-term results for people with long-lasting AF.
Read the detailed description
Atrial fibrillation (AF), often called AFib, is the most common type of irregular heartbeat. Normally, the heart beats in a steady rhythm. In AF, the upper chambers of the heart (the atria) beat very fast and irregularly, which prevents blood from being pumped out completely. People with AF may feel heart palpitations (a racing or fluttering feeling), dizziness, shortness of breath, fatigue, and chest discomfort. Over time, AF increases the risk of blood clots, stroke, heart failure, and other serious health problems.
What is long-standing persistent AF?
AF is classified by how long it lasts. This study focuses on long-standing persistent AF, which is defined as continuous AF that lasts for more than 12 months. In this form of AF, the heart's upper chambers have undergone significant changes-often called "atrial remodeling." These changes make the heart tissue more prone to sustaining irregular rhythms and make the condition harder to treat compared to shorter-lasting forms of AF. Many patients with long-standing persistent AF continue to have symptoms even after trying antiarrhythmic medications (drugs designed to control heart rhythm), and finding an effective treatment remains a challenge.
Why is this study needed?
Catheter ablation is a procedure that uses energy to create small scars in specific areas of the heart to block abnormal electrical signals. Pulmonary vein isolation (PVI) is the standard ablation procedure for AF, where the doctor isolates the areas where most abnormal signals start. However, in patients with long-standing persistent AF, PVI alone is often not enough. Studies show that only about half of patients remain in normal heart rhythm 12 months after PVI alone. Researchers believe that additional ablation lines-created along specific pathways outside the pulmonary veins-may help block more abnormal electrical circuits and improve outcomes. The main challenge is that doctors do not yet know which combination of ablation lines works best.
Newer energy technologies may also help. Pulsed field ablation (PFA) is a new, non-thermal ablation technology that uses short, high-voltage electrical pulses to kill heart cells that cause abnormal signals. Unlike traditional heat-based methods (such as radiofrequency ablation), PFA is more selective. It targets heart tissue while causing less damage to nearby structures like the esophagus (the tube connecting the throat to the stomach) and the phrenic nerves (which control breathing). This makes PFA potentially safer for treating areas near these sensitive structures. Radiofrequency (RF) ablation uses heat and remains a reliable method for creating precise, targeted lesions. This study combines both technologies: PFA for isolating the pulmonary veins and the back wall of the left atrium, and RF for creating additional linear lesions.
What does this study aim to find out?
The main goal of this study is to determine whether adding extra ablation lines-specifically the mitral isthmus line (supplemented by ethanol infusion into the vein of Marshall) and the cavotricuspid isthmus line-to the standard PVI plus posterior wall isolation can help more patients with long-standing persistent AF stay in normal heart rhythm at 12 months after the procedure. The study will also compare the two treatment groups in terms of safety, procedure time, AF burden, quality of life, and other health outcomes.
What type of study is this?
This is a prospective, multicenter, randomized, controlled trial. "Prospective" means participants are followed forward in time. "Multicenter" means the study is being conducted at multiple hospitals. "Randomized" means participants are assigned to one of two treatment groups by chance (like flipping a coin) to ensure that the groups are similar and the results are reliable. "Controlled" means the outcomes of the new treatment are compared against a standard treatment.
How many people will take part?
A total of 430 participants will be enrolled across multiple centers in China.
Who can join?
To be eligible, participants must:
Be between 18 and 75 years old
Have long-standing persistent AF that has lasted between 1 and 3 years
Have symptoms of AF (such as palpitations, fatigue, or shortness of breath) that did not improve after trying at least one antiarrhythmic medication
Have a documented AF episode within the 3 years before joining the study
Be willing and able to follow the study procedures and sign an informed consent form
Participants cannot join if they have certain other heart conditions (such as previous heart surgery or a left atrial thrombus), have had a previous AF ablation procedure, have a left atrial diameter larger than 55 mm, have severely reduced heart pumping function, or have other serious medical conditions that would make study participation unsafe.
What happens during the study?
After joining the study, participants will be randomly assigned to one of two groups.
Group 1 (Control group) - Standard ablation: Participants in this group will receive PFA to isolate the pulmonary veins (the large veins that carry blood from the lungs to the heart) and to create a "box lesion" that isolates the posterior wall of the left atrium. This combination (PVI plus posterior wall isolation) is currently a common approach for treating long-standing persistent AF.
Group 2 (Study group) - Modified linear ablation: Participants in this group will receive the same PFA to isolate the pulmonary veins and the posterior wall of the left atrium. In addition, they will receive ethanol infusion in the vein of Marshall, and receive RF ablation to create two extra linear lesions:
Mitral isthmus (MI) line - an ablation line along the area between the mitral valve (which controls blood flow between the left atrium and left ventricle) and the left inferior pulmonary vein. This ablation is supplemented by infusing a small amount of alcohol (ethanol) into the vein of Marshall (a small vein in the heart wall) to help create a more complete and lasting block.
Cavotricuspid isthmus (CTI) line - an ablation line at the bottom of the right atrium that targets abnormal electrical signals that can cause a different type of fast heartbeat called atrial flutter.
Both procedures are performed under sedation or general anesthesia (medication to make the participant sleep and not feel pain). The doctor guides a thin, flexible tube called a catheter through a vein in the leg up to the heart to deliver the ablation energy.
What is the follow-up schedule?
Participants will be followed for 12 months after the procedure. Follow-up visits will occur at 1 month, 3 months, 6 months, 9 months, and 12 months. At these visits, participants will undergo:
Physical exams
Electrocardiograms (ECGs, which record the heart's electrical activity)
24-hour Holter monitoring (at 1 and 3 months) or 3-day Holter monitoring (at 6, 9, and 12 months) - these are portable heart rhythm recorders that the participant wears at home
Echocardiograms (at 3, 6, and 12 months) - an ultrasound of the heart to check its structure and function
Quality of life questionnaires (the AFEQT and EQ-5D-5L surveys) to assess how AF and the treatment affect daily life
Neurocognitive assessments to evaluate memory and thinking skills
Recording of any symptoms, medications, or health events between visits
In addition, participants will be asked to use a portable heart monitor whenever they feel heart symptoms between scheduled visits.
What is the main outcome being measured?
The primary outcome is the percentage of participants who remain in normal sinus rhythm (regular heart rhythm) at 12 months after the procedure, excluding a 3-month blanking period right after the procedure when the heart is healing and temporary rhythm changes do not count as failure. This means that between 3 months and 12 months after the procedure, participants must not have any episode of AF, atrial flutter, or atrial tachycardia lasting more than 30 seconds, recorded by ECG or Holter monitor.
What other outcomes will be measured?
Secondary outcomes include:
The need for repeat ablation or electrical cardioversion (a procedure that uses a small electric shock to restore normal rhythm)
AF burden (the total amount of time the heart spends in AF over the follow-up period)
Procedure time, ablation time, and radiation exposure during the procedure
Improvement in quality of life scores
Changes in cognitive function
Occurrence of any complications or adverse events
What are the risks?
As with any medical procedure, catheter ablation carries risks. Possible risks include bleeding or infection at the catheter insertion site, bruising, damage to blood vessels, perforation of the heart wall (which may require drainage), stroke or blood clot, damage to the phrenic nerve (which could affect breathing), narrowing of the pulmonary veins, and formation of a fistula (an abnormal connection) between the left atrium and the esophagus. PFA is a newer technology that may have a lower risk of certain complications-such as damage to the esophagus or phrenic nerve-compared to traditional heat-based ablation methods. However, as with any new medical device, there may be unknown risks. The ethanol infusion into the vein of Marshall carries its own small risks, including pain, spasm of the heart artery, or inflammation around the heart. The study doctor will explain all known risks before asking for consent, and participants will be closely monitored for any complications.
What are the possible benefits?
Participants in the study group may benefit from the additional ablation lines, which could lower their chance of AF returning compared to the standard approach. Participants in both groups may experience fewer AF symptoms, better heart function, and an improved quality of life. However, there is no guarantee of benefit, and some participants may not improve. The results of this study may also help future patients with long-standing persistent AF by providing evidence to guide treatment decisions.
How will participant privacy be protected?
All participant information will be kept confidential. Participants will be identified by a unique study number rather than by name in any study records or reports. The study results will be published only as summary data, without any information that could identify individual participants.
Who is conducting this study?
This study is led by the Department of Cardiology at Beijing Anzhen Hospital, Capital Medical University, in collaboration with multiple centers across China.
Study period
The study will enroll participants from approximately June 2026 to December 2027, with follow-up completed by December 2028. The total study period is approximately 3.5 years.
- Being tested
- Linear ablation of mitral isthmus and tricuspid isthmus, Ethanol, Radiofrequency Ablation Catheter
- Keywords
- Atrial Fibrillation, Catheter Ablation, Long-standing Persistent Atrial Fibrillation, Pulsed Field Ablation, Radiofrequency Ablation
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Linear ablation of mitral isthmus and tricuspid isthmusProcedure or surgery
Use of a pentaspline pulsed field ablation (PFA) catheter to perform circumferential pulmonary vein isolation (PVI) and left atrial posterior wall box isolation. The endpoint is confirmed bidirectional block of all targeted veins and the posterior wall.
EthanolDrug
Infusion of absolute ethanol into the vein of Marshall (VOM) under balloon occlusion to facilitate mitral isthmus linear ablation.
Radiofrequency Ablation CatheterProcedure or surgery
Use of a contact-force sensing radiofrequency (RF) ablation catheter to create modified linear lesions: mitral isthmus line (combined with ethanol infusion) and cavotricuspid isthmus line. The goal is bidirectional block across all linear lesions.
| Study group | Role | What they receive |
|---|---|---|
| Pulmonary Vein Isolation + Posterior Wall Isolation (PFA Only) | Active comparator | Participants in this arm receive pulsed-field ablation (PFA) to isolate all four pulmonary veins and to create a box lesion isolating the left atrial posterior wall. No additional linear ablation lines are performed. The procedure endpoint is confirmed bidirectional block of all targeted veins and the posterior wall. CTI ablation will be performed only if typical atrial flutter is documented. Receives: Procedure: Linear ablation of mitral isthmus and tricuspid isthmus |
| PVI + Posterior Wall + Modified Linear Ablation (PFA + RF) | Experimental | Participants in this arm receive the same PFA-based pulmonary vein isolation and posterior wall box isolation as the control arm. In addition, they undergo modified linear ablation using radiofrequency (RF) energy. This includes:
Mitral isthmus line supplemented by ethanol infusion into the vein of Marshall.
Cavotricuspid isthmus line. The goal is to achieve bidirectional block across all ablation lines. Receives: Procedure: Linear ablation of mitral isthmus and tricuspid isthmus; Drug: Ethanol; Procedure: Radiofrequency Ablation Catheter |
What is being measured
The primary outcome is the main question the study is designed to answer.
Freedom from Atrial Arrhythmia Recurrence at 12 Months
The primary outcome is the proportion of participants remaining in normal sinus rhythm at 12 months after the ablation procedure, after excluding a 3-month blanking period immediately following the procedure. Treatment success is defined as freedom from any documented episode of atrial fibrillation, atrial flutter, or atrial tachycardia lasting more than 30 seconds, as recorded by electrocardiogram (ECG) or Holter monitoring between 3 months and 12 months post-ablation.
Measured: Between 3 months and 12 months following the ablation procedure, excluding the initial 3-month blanking period
Secondary outcomes (7)
Atrial Fibrillation Burden at 12 Months
AF burden is defined as the percentage of time spent in atrial fibrillation (AF), atrial flutter, or atrial tachycardia during the 12-month follow-up period, excluding the 3-month blanking period. Burden is assessed using 24-hour Holter monitoring at 6 and 9 months and 7-day Holter monitoring at 12 months post-ablation. The percentage of AF days (defined as days on which Holter recording shows any AF/AFL/AT episode) among total monitored days will also be reported as a secondary measure.
Measured: From month 3 to month 12 after the ablation procedure
Incidence of Serious Procedure-Related Complications
Proportion of participants experiencing at least one serious adverse event related to the ablation procedure or device. Serious complications include cardiac tamponade requiring intervention, atrio-esophageal fistula, periprocedural stroke or transient ischemic attack, pulmonary vein stenosis, hemolysis requiring renal replacement therapy, coronary events (including spasm requiring unplanned angiography), and death.
Measured: From the start of the ablation procedure to 30 days post-procedure
Cardiovascular Hospitalization During Follow-up
Any hospitalization for cardiovascular causes (including heart failure, arrhythmia recurrence, stroke, or other cardiac events) during the 12-month follow-up period after ablation.
Measured: From the date of ablation to 12 months post-ablation
Total Procedure Time
Total procedure time measured in minutes from first femoral venous access to final sheath removal.
Measured: On the day of the ablation procedure
Acute Success Rates of Linear Ablation Lesions
Procedural success for linear ablation lesions is defined as confirmed bidirectional block of the target lesion immediately after ablation, assessed by electroanatomic mapping and differential pacing maneuvers. The following specific lesion sets are evaluated:
Posterior wall isolation rate: Proportion of participants in whom complete bidirectional block of the left atrial posterior wall box lesion is achieved. This is assessed in both study groups.
Mitral isthmus line block rate: Proportion of participants in the study group (modified linear ablation arm) in whom bidirectional block of the mitral isthmus line is confirmed after combined ethanol infusion into the vein of Marshall and radiofrequency ablation.
Cavotricuspid isthmus line block rate: Proportion of participants in the study group in whom bidirectional block of the cavotricuspid isthmus line is confirmed (only performed if typical atrial flutter is documented, otherwise not applicable).
Measured: During the ablation procedure (intraoperative)
Change in AFEQT Overall Score at 12 Months
The Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire is a 20-item, disease-specific, patient-reported instrument. It assesses the impact of atrial fibrillation on health-related quality of life across four subscales: symptoms (4 items), daily activities (8 items), treatment concerns (6 items), and treatment satisfaction (2 items). Each item is scored on a 7-point Likert scale. The overall summary score ranges from 0 to 100, with higher scores indicating better quality of life. A change of 5 points or more is considered clinically meaningful. The outcome is the change from baseline in the AFEQT overall score at each follow-up time point.
Measured: Baseline and at 3 and 12 months after the ablation procedure
Change in Montreal Cognitive Assessment (MoCA) Score at 12 Months
The Montreal Cognitive Assessment (MoCA) is a clinician-administered screening tool designed to detect mild cognitive impairment (MCI). It assesses multiple cognitive domains including visuospatial/executive function, naming, attention, language, abstraction, delayed recall, and orientation. Total scores range from 0 to 30, with higher scores indicating better cognitive function. A score of ≥26 is generally considered normal. The MoCA has greater sensitivity for detecting mild cognitive impairment compared to the MMSE. The outcome is the change from baseline in the total MoCA score at each follow-up time point.
Measured: Baseline and at 3 and 12 months after the ablation procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study start27 Jul 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned in a 1:1 ratio to one of two parallel groups. The control group receives pulsed-field ablation (PFA) for pulmonary vein isolation and posterior wall isolation. The study group receives the same PFA procedure plus additional modified linear ablation using radiofrequency energy (mitral isthmus line supplemented by ethanol infusion into the vein of Marshall, and cavotricuspid isthmus line). No cross-over between groups is planned.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 430 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yunlong Wang
- Sponsor type
- University, hospital or other
- Collaborators
- Beijing Huahsia Foundation, Boston Scientific Corporation
- Responsible party
- Sponsor-investigator, Yunlong Wang, Beijing Anzhen Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07633509
- Sponsor's protocol ID
- The COMBINE-AF Trial
- Acronym
- COMBINE-AF
- Status last verified
- Jul 2026
- First submitted
- 2 Jun 2026
- Last updated
- 27 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Prospective, Randomized Controlled Trial of Combined Pulsed-Field and Radiofrequency-Modified Linear Ablation Versus Pulsed-Field Ablation Alone for Long-Standing Persistent Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT07633509
- Acronym / sponsor ID
- COMBINE-AF / The COMBINE-AF Trial
- Keywords
- Atrial Fibrillation, Catheter Ablation, Long-standing Persistent Atrial Fibrillation, Pulsed Field Ablation, Radiofrequency Ablation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 430 participants (estimated)
- Lead sponsor
- Yunlong WangUniversity, hospital or other
- Collaborators
- Beijing Huahsia Foundation, Boston Scientific Corporation
- Study start
- 27 Jul 2026 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 8 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test if a more complete ablation procedure works better than the standard procedure for people with long-lasting persistent atrial fibrillation (AF). AF is a heart rhythm problem that can cause a fast or uneven heartbeat.
This study will include 430 people with long-lasting AF that has lasted 1 to 3 years. Participants will be put into one of two groups by chance:
First group (control): They will receive pulsed-field ablation (PFA), a type of energy that can stop the faulty heart signals. They will have isolation of the pulmonary veins and the posterior wall of the left atrium.
Second group (study): They will receive the same PFA procedure plus extra ablation lines (modified linear ablation) using radiofrequency energy. This includes ablation of the mitral isthmus (with ethanol infusion into a small vein called the vein of Marshall) and the cavotricuspid isthmus.
Participants will be followed for 12 months after the procedure with clinic visits, electrocardiograms (ECGs), and heart rhythm monitors. The main outcome is whether participants stay in normal heart rhythm (sinus rhythm) without any AF episodes lasting more than 30 seconds at 12 months. Researchers will also look at procedure time, complication rates, quality of life, and other rhythm outcomes.
This study will help show if the more complete ablation procedure leads to better long-term results for people with long-lasting AF.
Detailed description
Atrial fibrillation (AF), often called AFib, is the most common type of irregular heartbeat. Normally, the heart beats in a steady rhythm. In AF, the upper chambers of the heart (the atria) beat very fast and irregularly, which prevents blood from being pumped out completely. People with AF may feel heart palpitations (a racing or fluttering feeling), dizziness, shortness of breath, fatigue, and chest discomfort. Over time, AF increases the risk of blood clots, stroke, heart failure, and other serious health problems.
What is long-standing persistent AF?
AF is classified by how long it lasts. This study focuses on long-standing persistent AF, which is defined as continuous AF that lasts for more than 12 months. In this form of AF, the heart's upper chambers have undergone significant changes-often called "atrial remodeling." These changes make the heart tissue more prone to sustaining irregular rhythms and make the condition harder to treat compared to shorter-lasting forms of AF. Many patients with long-standing persistent AF continue to have symptoms even after trying antiarrhythmic medications (drugs designed to control heart rhythm), and finding an effective treatment remains a challenge.
Why is this study needed?
Catheter ablation is a procedure that uses energy to create small scars in specific areas of the heart to block abnormal electrical signals. Pulmonary vein isolation (PVI) is the standard ablation procedure for AF, where the doctor isolates the areas where most abnormal signals start. However, in patients with long-standing persistent AF, PVI alone is often not enough. Studies show that only about half of patients remain in normal heart rhythm 12 months after PVI alone. Researchers believe that additional ablation lines-created along specific pathways outside the pulmonary veins-may help block more abnormal electrical circuits and improve outcomes. The main challenge is that doctors do not yet know which combination of ablation lines works best.
Newer energy technologies may also help. Pulsed field ablation (PFA) is a new, non-thermal ablation technology that uses short, high-voltage electrical pulses to kill heart cells that cause abnormal signals. Unlike traditional heat-based methods (such as radiofrequency ablation), PFA is more selective. It targets heart tissue while causing less damage to nearby structures like the esophagus (the tube connecting the throat to the stomach) and the phrenic nerves (which control breathing). This makes PFA potentially safer for treating areas near these sensitive structures. Radiofrequency (RF) ablation uses heat and remains a reliable method for creating precise, targeted lesions. This study combines both technologies: PFA for isolating the pulmonary veins and the back wall of the left atrium, and RF for creating additional linear lesions.
What does this study aim to find out?
The main goal of this study is to determine whether adding extra ablation lines-specifically the mitral isthmus line (supplemented by ethanol infusion into the vein of Marshall) and the cavotricuspid isthmus line-to the standard PVI plus posterior wall isolation can help more patients with long-standing persistent AF stay in normal heart rhythm at 12 months after the procedure. The study will also compare the two treatment groups in terms of safety, procedure time, AF burden, quality of life, and other health outcomes.
What type of study is this?
This is a prospective, multicenter, randomized, controlled trial. "Prospective" means participants are followed forward in time. "Multicenter" means the study is being conducted at multiple hospitals. "Randomized" means participants are assigned to one of two treatment groups by chance (like flipping a coin) to ensure that the groups are similar and the results are reliable. "Controlled" means the outcomes of the new treatment are compared against a standard treatment.
How many people will take part?
A total of 430 participants will be enrolled across multiple centers in China.
Who can join?
To be eligible, participants must:
Be between 18 and 75 years old
Have long-standing persistent AF that has lasted between 1 and 3 years
Have symptoms of AF (such as palpitations, fatigue, or shortness of breath) that did not improve after trying at least one antiarrhythmic medication
Have a documented AF episode within the 3 years before joining the study
Be willing and able to follow the study procedures and sign an informed consent form
Participants cannot join if they have certain other heart conditions (such as previous heart surgery or a left atrial thrombus), have had a previous AF ablation procedure, have a left atrial diameter larger than 55 mm, have severely reduced heart pumping function, or have other serious medical conditions that would make study participation unsafe.
What happens during the study?
After joining the study, participants will be randomly assigned to one of two groups.
Group 1 (Control group) - Standard ablation: Participants in this group will receive PFA to isolate the pulmonary veins (the large veins that carry blood from the lungs to the heart) and to create a "box lesion" that isolates the posterior wall of the left atrium. This combination (PVI plus posterior wall isolation) is currently a common approach for treating long-standing persistent AF.
Group 2 (Study group) - Modified linear ablation: Participants in this group will receive the same PFA to isolate the pulmonary veins and the posterior wall of the left atrium. In addition, they will receive ethanol infusion in the vein of Marshall, and receive RF ablation to create two extra linear lesions:
Mitral isthmus (MI) line - an ablation line along the area between the mitral valve (which controls blood flow between the left atrium and left ventricle) and the left inferior pulmonary vein. This ablation is supplemented by infusing a small amount of alcohol (ethanol) into the vein of Marshall (a small vein in the heart wall) to help create a more complete and lasting block.
Cavotricuspid isthmus (CTI) line - an ablation line at the bottom of the right atrium that targets abnormal electrical signals that can cause a different type of fast heartbeat called atrial flutter.
Both procedures are performed under sedation or general anesthesia (medication to make the participant sleep and not feel pain). The doctor guides a thin, flexible tube called a catheter through a vein in the leg up to the heart to deliver the ablation energy.
What is the follow-up schedule?
Participants will be followed for 12 months after the procedure. Follow-up visits will occur at 1 month, 3 months, 6 months, 9 months, and 12 months. At these visits, participants will undergo:
Physical exams
Electrocardiograms (ECGs, which record the heart's electrical activity)
24-hour Holter monitoring (at 1 and 3 months) or 3-day Holter monitoring (at 6, 9, and 12 months) - these are portable heart rhythm recorders that the participant wears at home
Echocardiograms (at 3, 6, and 12 months) - an ultrasound of the heart to check its structure and function
Quality of life questionnaires (the AFEQT and EQ-5D-5L surveys) to assess how AF and the treatment affect daily life
Neurocognitive assessments to evaluate memory and thinking skills
Recording of any symptoms, medications, or health events between visits
In addition, participants will be asked to use a portable heart monitor whenever they feel heart symptoms between scheduled visits.
What is the main outcome being measured?
The primary outcome is the percentage of participants who remain in normal sinus rhythm (regular heart rhythm) at 12 months after the procedure, excluding a 3-month blanking period right after the procedure when the heart is healing and temporary rhythm changes do not count as failure. This means that between 3 months and 12 months after the procedure, participants must not have any episode of AF, atrial flutter, or atrial tachycardia lasting more than 30 seconds, recorded by ECG or Holter monitor.
What other outcomes will be measured?
Secondary outcomes include:
The need for repeat ablation or electrical cardioversion (a procedure that uses a small electric shock to restore normal rhythm)
AF burden (the total amount of time the heart spends in AF over the follow-up period)
Procedure time, ablation time, and radiation exposure during the procedure
Improvement in quality of life scores
Changes in cognitive function
Occurrence of any complications or adverse events
What are the risks?
As with any medical procedure, catheter ablation carries risks. Possible risks include bleeding or infection at the catheter insertion site, bruising, damage to blood vessels, perforation of the heart wall (which may require drainage), stroke or blood clot, damage to the phrenic nerve (which could affect breathing), narrowing of the pulmonary veins, and formation of a fistula (an abnormal connection) between the left atrium and the esophagus. PFA is a newer technology that may have a lower risk of certain complications-such as damage to the esophagus or phrenic nerve-compared to traditional heat-based ablation methods. However, as with any new medical device, there may be unknown risks. The ethanol infusion into the vein of Marshall carries its own small risks, including pain, spasm of the heart artery, or inflammation around the heart. The study doctor will explain all known risks before asking for consent, and participants will be closely monitored for any complications.
What are the possible benefits?
Participants in the study group may benefit from the additional ablation lines, which could lower their chance of AF returning compared to the standard approach. Participants in both groups may experience fewer AF symptoms, better heart function, and an improved quality of life. However, there is no guarantee of benefit, and some participants may not improve. The results of this study may also help future patients with long-standing persistent AF by providing evidence to guide treatment decisions.
How will participant privacy be protected?
All participant information will be kept confidential. Participants will be identified by a unique study number rather than by name in any study records or reports. The study results will be published only as summary data, without any information that could identify individual participants.
Who is conducting this study?
This study is led by the Department of Cardiology at Beijing Anzhen Hospital, Capital Medical University, in collaboration with multiple centers across China.
Study period
The study will enroll participants from approximately June 2026 to December 2027, with follow-up completed by December 2028. The total study period is approximately 3.5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will be randomly assigned in a 1:1 ratio to one of two parallel groups. The control group receives pulsed-field ablation (PFA) for pulmonary vein isolation and posterior wall isolation. The study group receives the same PFA procedure plus additional modified linear ablation using radiofrequency energy (mitral isthmus line supplemented by ethanol infusion into the vein of Marshall, and cavotricuspid isthmus line). No cross-over between groups is planned.
| Arm | Type | Receives |
|---|---|---|
| Pulmonary Vein Isolation + Posterior Wall Isolation (PFA Only) | Active comparator | Procedure: Linear ablation of mitral isthmus and tricuspid isthmusParticipants in this arm receive pulsed-field ablation (PFA) to isolate all four pulmonary veins and to create a box lesion isolating the left atrial posterior wall. No additional linear ablation lines are performed. The procedure endpoint is confirmed bidirectional block of all targeted veins and the posterior wall. CTI ablation will be performed only if typical atrial flutter is documented. |
| PVI + Posterior Wall + Modified Linear Ablation (PFA + RF) | Experimental | Procedure: Linear ablation of mitral isthmus and tricuspid isthmus, Drug: Ethanol, Procedure: Radiofrequency Ablation CatheterParticipants in this arm receive the same PFA-based pulmonary vein isolation and posterior wall box isolation as the control arm. In addition, they undergo modified linear ablation using radiofrequency (RF) energy. This includes: Mitral isthmus line supplemented by ethanol infusion into the vein of Marshall. Cavotricuspid isthmus line. The goal is to achieve bidirectional block across all ablation lines. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Symptomatic patients with long-standing persistent atrial fibrillation.
- Duration of atrial fibrillation between 1 and 3 years.
- Age 18 to 75 years.
- Documentation of atrial fibrillation within 3 years prior to enrollment.
- Willing and able to comply with the study protocol and provide written informed consent.
Key exclusion criteria (30 listed)
- Paroxysmal atrial fibrillation, or evidence of sinus rhythm on electrocardiogram within the past year.
- Persistent atrial fibrillation lasting less than 1 year or more than 3 years.
- Left atrial thrombus.
- Prior catheter ablation for atrial fibrillation.
- Coexisting severe organic heart disease (e.g., severe valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Linear ablation of mitral isthmus and tricuspid isthmusUse of a pentaspline pulsed field ablation (PFA) catheter to perform circumferential pulmonary vein isolation (PVI) and left atrial posterior wall box isolation. The endpoint is confirmed bidirectional block of all targeted veins and the posterior wall. | Procedure or surgery | PVI + Posterior Wall + Modified Linear Ablation (PFA + RF), Pulmonary Vein Isolation + Posterior Wall Isolation (PFA Only) |
| EthanolInfusion of absolute ethanol into the vein of Marshall (VOM) under balloon occlusion to facilitate mitral isthmus linear ablation. | Drug | PVI + Posterior Wall + Modified Linear Ablation (PFA + RF) |
| Radiofrequency Ablation CatheterUse of a contact-force sensing radiofrequency (RF) ablation catheter to create modified linear lesions: mitral isthmus line (combined with ethanol infusion) and cavotricuspid isthmus line. The goal is bidirectional block across all linear lesions. | Procedure or surgery | PVI + Posterior Wall + Modified Linear Ablation (PFA + RF) |
Primary outcome
Freedom from Atrial Arrhythmia Recurrence at 12 Months
Time frame: Between 3 months and 12 months following the ablation procedure, excluding the initial 3-month blanking period
The primary outcome is the proportion of participants remaining in normal sinus rhythm at 12 months after the ablation procedure, after excluding a 3-month blanking period immediately following the procedure. Treatment success is defined as freedom from any documented episode of atrial fibrillation, atrial flutter, or atrial tachycardia lasting more than 30 seconds, as recorded by electrocardiogram (ECG) or Holter monitoring between 3 months and 12 months post-ablation.
7 secondary outcomes
Atrial Fibrillation Burden at 12 Months
Time frame: From month 3 to month 12 after the ablation procedure
Incidence of Serious Procedure-Related Complications
Time frame: From the start of the ablation procedure to 30 days post-procedure
Cardiovascular Hospitalization During Follow-up
Time frame: From the date of ablation to 12 months post-ablation
Total Procedure Time
Time frame: On the day of the ablation procedure
Acute Success Rates of Linear Ablation Lesions
Time frame: During the ablation procedure (intraoperative)
Change in AFEQT Overall Score at 12 Months
Time frame: Baseline and at 3 and 12 months after the ablation procedure
Change in Montreal Cognitive Assessment (MoCA) Score at 12 Months
Time frame: Baseline and at 3 and 12 months after the ablation procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Atrial Fibrillation (AF)
RecruitingObservational study
BOdygUardian MOnitoriNg for ReCurrencE of AF
Atrial Fibrillation (AF)
Active, not recruitingObservational study
Resumption of Anticoagulation After Major Gastrointestinal Bleeding in Patients With Atrial Fibrillation
Atrial Fibrillation (AF), Gastrointestinal Bleeding
Recruiting
A Comparison of Pulsed Field Ablation (PFA) vs Cryoablation for Atrial Fibrillation Under Deep Sedation
Atrial Fibrillation (AF)
Not yet recruiting
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
Atrial Fibrillation (AF)
RecruitingObservational study
PULSED AF Post-Approval Study
Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yijie Liu, PhD contact
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Linear ablation of mitral isthmus and tricuspid isthmus, Ethanol and Radiofrequency Ablation Catheter in people with Atrial Fibrillation (AF) and Atrial Fibrillation Catheter Ablation, run by Yunlong Wang at 3 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yunlong Wang, PhD (+86 10 81992202, yunlong76818@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Freedom from Atrial Arrhythmia Recurrence at 12 Months (time frame: Between 3 months and 12 months following the ablation procedure, excluding the initial 3-month blanking period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.